Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 10,000 shares at $1.98 ($20K) on 2015-07-06, disclosed to the SEC on 2015-07-08.
Scheduled sale ($20k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.92 | 1,300 | $2K | 12.8% |
| 2 | $1.93 | 1,700 | $3K | 16.8% |
| 3 | $1.93 | 700 | $1K | 6.9% |
| 4 | $1.93 | 100 | $193 | 1.0% |
| 5 | $1.95 | 400 | $780 | 4.0% |
| 6 | $1.95 | 1,200 |
| $2K |
| 12.0% |
| 7 | $1.96 | 1,000 | $2K | 10.0% |
| 8 | $1.97 | 700 | $1K | 7.1% |
| 9 | $1.97 | 444 | $875 | 4.5% |
| 10 | $1.98 | 200 | $396 | 2.0% |
| 11 | $1.98 | 2,256 | $4K | 22.9% |
| Total | $1.95 avg | 10,000 | $20K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |